Clinical Oncologist at Grupo Oncoclínicas discusses phase II DESTINY-Breast01 study and meta-analysis that included four randomized clinical trials involving patients with triple-negative breast cancer
The ESMO Breast Cancer 2021 event, held between May 5 and 8, addressed important topics related to breast tumors.
Dr. Cesar Martins da Costa, Master’s degree in Medicine at UNESP and Clinical Oncologist at Grupo Oncoclínicas in São Paulo, discusses, in the video below, two studies of great relevance presented during the event:
Watch the video and check out the expert’s comments:
Legal Notice: All content of this portal has been developed and will be constantly updated by Oncologia Brasil, independently and autonomously, without any interference from the sponsoring companies and without any obligation of its professionals in relation to the recommendation or prescription of products of one of the companies. The information provided on this portal does not replace the relationship between the internet user and the doctor. Always consult your doctor.